Author(s)
On 2 October 2020, the American Food & Drug Administration approved a combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co) and ipilimumab (YERVOY, Bristol-Myers Squibb Co) as a first-line treatment for adults with unresectable mesothelioma. Randomised open-label trials suggest an improvement in overall survival in the order of approximately 25% when compared with chemotherapy.
The full announcement is available here.
As yet, the treatment is not approved for use in the UK.
On 10 April 2024, the High Court handed down its decision in Williams-Henry v Associated British Ports Holdings Ltd [2024] EWHC 806 (KB). In that judgment the presentation of the Claimant’s claim for personal injury was considered fundamentally dishonest and so was dismissed under section 57 of the Criminal Justice and Courts Act 2015 (“the 2015 Act”). In considering whether…
After the introduction of the reforms to the Civil Procedure Rules in 2013, you may recall some judges becoming, at least initially, excited about the prospect of experts giving evidence concurrently (so-called “hot tubbing”). Since that early flush of excitement, I have been involved in only one trial in which it was used and I…
Provisional damages operate as an exception to the general rule that damages are assessed on a once-and-for-all basis. Where a claimant finds themselves at a risk of developing a disease or deterioration in their physical or mental condition in the future, the general rule would require the court to assess that risk and compensate the…
